SM
TNXP icon

Sabby Management’s Tonix Pharmaceuticals TNXP Stock Holding History

Sabby Management’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,530
Closed -$911K – 62
2024
Q1 		$911K Buy
1,530
+563
+58% +$606K 0.53% 9
2023
Q4 		$1.25M Buy
967
+577
+148% +$929K 1.25% 3
2023
Q3 		$680K Buy
+390
New +$1.43M 0.5% 10
2019
Q1 		– Hold
0
– -$653K – 125
2018
Q4 		– Hold
0
– – – 42
2016
Q4 		– Hold
0
– -$142K – 330
2016
Q3 		– Hold
0
– – – 283
2016
Q2 		– Hold
0
– – – 152
2016
Q1 		– Hold
0
– – – 162
2015
Q4 		– Hold
0
– – – 167
2015
Q3 		– Hold
0
– – – 258
2015
Q2 		– Hold
0
– – – 291
2015
Q1 		– Hold
0
– – – 265
2014
Q4 		– Hold
0
– -$345 – 275
2014
Q3 		– Hold
0
– – – 200
2014
Q2 		– Hold
0
– – – 85
2014
Q1 		– Hold
0
– – – 84

Other funds holding TNXP

Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sabby Management's TNXP Position: Q2 2024 in Review

Sabby Management sold out of Tonix Pharmaceuticals (TNXP) in Q2 2024, closing a stake of 1,530 shares — an estimated $911K sold.

Sabby Management first reported a position in TNXP in Q3 2023 and held it in 3 quarters. The position peaked at $1.25M in Q4 2023. 13 funds tracked by Wall St. Rank hold TNXP as of Q2 2024.

  • Sabby Management reported no remaining Tonix Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Sabby Management sold 1,530 Tonix Pharmaceuticals shares in Q2 2024, an estimated $911K.
  • Sabby Management first reported a position in Tonix Pharmaceuticals in Q3 2023 and held it in 3 quarters.
  • Sabby Management's Tonix Pharmaceuticals position peaked at $1.25M in Q4 2023.
  • 13 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2024.

Based on Sabby Management's 13F filing for Q2 2024, filed 14 Aug 2024.